Glaucoma Therapeutics Market Insights:
The global glaucoma therapeutics market is anticipated to gain traction in the future. Projected CAGR is pegged at 2.9% for the forecast period (2020-2026). The market is slated to reach a valuation of US$ 7.6 Bn. It is established that glaucoma affects 2% of the world’s population. The number increases with passing age, accounting for almost one-tenth of the population aged 70 years and above.
Moreover, people afflicted with diabetes are more likely to experience vision related problems as high blood sugar leads to diabetic retinopathy. However, the COVID-19 outbreak is poised to slow down the pace of volumes for certain therapeutic drugs. Fortunately, supply chain disruptions are anticipated to remain absent as companies have adequate inventory.
Glaucoma Therapeutics Market: Technological Insights:
Several technological advancements in drug delivery are anticipated to leverage the scope of glaucoma therapeutics. These advancements include: implantable extended-release devices, polymer-based contact lenses and intraocular delivery technologies. Other options include drug-eluting punctal plugs, microneedle-injection devices and micro-dosing technology. These approaches were elaborated upon at the Glaucoma 360 New Horizons Forum in San Francisco in February 2020.
These approaches are anticipated to significantly enhance the quality of life of glaucoma patients and provide more effective therapies to better preserve vision in glaucoma. Another technological development is the Eyemate intraocular sensor, which offers a new way to reliably measure 24 h intraocular pressure. The sensor is designed to stay in the patient’s eye indefinitely. It does not require any battery. It derives its power through electromagnetic inductive coupling to an external magnetic field generator.
Glaucoma Therapeutics Market: Drug Applications Insights:
Prostaglandins are expected to find widespread usage for treating glaucoma among patients. Usage of these drugs as the first line of treatment is expected to be the driving force behind the growth of this segment. The segment is forecast to register a market share of 44% during the forecast period.
The combined medication segment shows a positive growth trajectory during the forecast period. This is attributed to greater effectiveness of treatment using combination drugs over individual medication. Projected market share for combination drugs is pegged at around one-fifth of the global glaucoma therapeutics market. An important development in this regard is the approval and launch of Aerie Pharmaceutical’s Rhopressa drug class. More than 70 combination drugs are in the pipeline during the forecast period.
Get the latest COVID-19 impact insights on the glaucoma therapeutics market by requesting for a report sample here
Glaucoma Therapeutics Market: Regional Insights
North America is set to be the most lucrative market for glaucoma therapeutic drugs during the forecast period, capturing nearly half of the market share. This is attributed to increasing focus on research and development of new combination drugs as well as availability of Rhopressa drugs in the market. The region is projected to expand at a CAGR of 2.7% between 2020 and 2026.
To get exhaustive regional insights on the glaucoma therapeutics market, ask an analyst here
Asia-Pacific is expected to register the highest growth in the glaucoma therapeutic drugs market, with combination medicines set to grow the fastest. The region shall capture nearly one-fourth of the overall glaucoma therapeutics market. A burgeoning population and introduction of new drugs is expected to drive market growth in Asia-Pacific. The introduction of drugs based on a combination of travoprost and timolol compounds is an example of such new drug development.
Glaucoma Therapeutics Market Leaders
The global glaucoma therapeutics market consists of the following market players: Allergan plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Santen Pharmaceuticals Co. Ltd., Valeant Pharmaceuticals, Inc. and Aerie Pharmaceuticals, Inc. Out of these, Novartis AG comprises the maximum market share of glaucoma therapeutics drugs. This is because of its Alcon division which focuses on development of eye care products. Some of its brands include Travatan, Simbrinza and Azarga, which contribute the maximum revenue share to Novartis’s revenue.
Allergan Plc., occupies the second position in the market, and include top selling brands like Lumigan, Alphagan, Ganfort and Combigan. More recently, the company also received an approval from the FDA to launch its DURYSTATM Biodegradable Sustained-Release Implant. This device is designed to reduce intraocular pressure in open-angle glaucoma or ocular hypertension patients.
COVID-19 Market Insights:
The COVID-19 pandemic is anticipated to moderately impact the glaucoma therapeutics market. Leading players are ensuring that the supply of critical products is not hampered. For instance, Alcon has initiated its Global Crisis Management program to implement business continuity measures and action plans. The company’s manufacturing sites are open and are working to mitigate supply chain disruptions. Valeant Pharmaceuticals, Inc., now known as Bausch Health, is directing its resources to tackle the COVID-19 pandemic. It is working with multiple health authorities to make VIRAZOLE available as a potential treatment for COVID-19.
Aerie Pharmaceuticals, however, has registered a decline in the pace of volumes of its Rocklatan and Rhopressa ophthalmic drugs in the first quarter of 2020. A positive partial offset has been witnessed from increasing three months’ supply activity. However, with many eye care professionals’ offices remaining closed, new prescription growth has slowed. Fortunately, no supply chain disruptions have been experienced for the Rocklatan and Rhopressa drugs. The company believes it has approximately three years of starting materials and active pharmaceutical ingredients in inventory. Additionally, an adequate supply of finished products for a period of six months is also available.
The glaucoma therapeutics market is poised to expand positively in the future. Increasing preference for combination drugs, coupled with technological breakthroughs in glaucoma treatment are key growth levers. Moreover, application of nanotechnology is poised to offer convenience to glaucoma patients and enhance their quality of life. Regionally, North America is set to dominate the glaucoma therapeutics market, while Asia-Pacific shows promising growth prospects. The recent COVID-19 outbreak is not anticipated to disrupt supply chains of key manufacturers engaged in producing glaucoma therapeutic drugs. This is attributed to implementation of business continuity plans and robust co-ordination across departments.
Glaucoma Therapeutics Market: Report Scope:
The recent study by Fact.MR on glaucoma therapeutics market incorporates a 6-year forecast period, elaborating on the key drivers, opportunities and restraints of the market. A detailed analysis of the market has been provided for each segment, in terms of value and growth. The key segments are: Drug Class and End-user.
A regional landscape has also been included, providing a detailed analysis across five geographies. These include North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA). Each region has been analyzed based on the segments highlighted above. A separate competition landscape has also been given. Detailed profiles of key manufactures, their revenue shares and product development have been elaborated upon. Additionally, a SWOT analysis of each players has also been incorporated.
Glaucoma therapeutics market- Scope of the Report
The recent study by Fact.MR on glaucoma therapeutics market offers a 6-year forecast between 2020 and 2026. The study analyzes crucial trends that are currently determining the growth of glaucoma therapeutics market. This report explicates on vital dynamics such as the drivers, restraints and opportunities for key market players along with key stakeholders as well as emerging players associated with the manufacturing of glaucoma therapeutic drugs. The study also provides dynamics that are responsible for influencing the future status of the glaucoma therapeutics market over the forecast period.
A detailed assessment of glaucoma therapeutics market value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in the report. A list of prominent companies operating in the glaucoma therapeutics market along with their product portfolio enhances the reliability of this comprehensive research study.
Glaucoma therapeutics market: Report Summary
The study offers a comprehensive analysis on diverse features including production capacities, demand, product developments, revenue generation and sales in Glaucoma Therapeutics market across the globe.
A comprehensive estimate on glaucoma therapeutics market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of glaucoma therapeutic drugs during the forecast period. Price point comparison by region with global average price is also considered in the study.
Glaucoma therapeutics market segmentation
Fact.MR has studied the glaucoma therapeutics market with detailed segmentation on the basis of drug class, end-users and key regions.
Ambulatory Surgical Centers
Carbonic Anhydrase Inhibitors
Middle East & Africa
“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”
Glaucoma therapeutics market: Analysis on market size evaluation
The glaucoma therapeutics market has been analyzed for each market segment, in terms of value (US$ Mn).
Market estimates at global and regional levels for glaucoma therapeutics is available in terms of “US$ Mn” for value, along with market attractiveness evaluation in the report. A Y-o-Y growth contrast on prominent glaucoma therapeutic segments, along with market attractiveness evaluation has been incorporated in the report.
Glaucoma therapeutics market: Inspected assessment on regional segments
Key sections have been elaborated in the glaucoma therapeutics market report, which have helped to deliver projection on the regional markets. These chapters include the regional macros (economic and business environment outlook), which are expected to have a momentous influence on the growth of glaucoma therapeutics market during the forecast period.
Country-specific valuation on demand for glaucoma therapeutics has been offered for each regional market, along with the market scope estimate and forecast, price index, and impact analysis of dynamics of prominence in regions and countries. Detailed breakup in terms of value for emerging countries has also been included in the report.
Glaucoma therapeutics market: In-depth analysis on competitive landscape
The report sheds light on the leading manufacturers of glaucoma therapeutic drugs along with their detailed profiles. Essential and up-to-date data information related to the market performers, who are principally engaged in the production of glaucoma therapeutic drugs, has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits the report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which includes essentials such as product portfolio, key strategies along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through the matrix for all the prominent players thus providing the readers with actionable insights, which helps in thoughtfully presenting market status, and predicting the competition level in Glaucoma Therapeutics market. Prominent manufacturers with established market presence in global glaucoma therapeutics market are Allergan plc, Merck & Co., Inc. Novartis AG, Pfizer Inc. Santen Pharmaceuticals Co. Ltd. Valeant Pharmaceuticals International, Plc and Aerie Pharmaceuticals, Inc.
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Glaucoma Therapeutics Market
4. Market Overview
4.3. Market Dynamics
4.4. Global Glaucoma Therapeutics Market Analysis and Forecasts, 2020–2026
4.5. Porter’s Five Force Analysis
5. Market Outlook
5.1. Value Chain Analysis
5.2. Disease Prevalence & Incidence Rate, by Region
5.3. Healthcare Industry Overview
5.4. Pipeline Analysis
6. Global Glaucoma Therapeutics Market Analysis and Forecasts, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2020–2026
6.3.2. Beta Blockers
6.3.3. Alpha Agonists
6.3.4. Carbonic Anhydrase Inhibitors
6.3.5. Combination Medications
6.4. Market Attractiveness, by Drug Class
7. Global Glaucoma Therapeutics Market Analysis and Forecasts, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2020–2026
7.3.2. Ophthalmic Clinics
7.3.3. Ambulatory Surgical Centers
7.4. Market Attractiveness, by End-user
8. Global Glaucoma Therapeutics Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region
9. North America Glaucoma Therapeutics Market Analysis and Forecast
9.2. Market Value Forecast, by Drug Class, 2020–2026
9.2.2. Beta Blockers
9.2.3. Alpha Agonists
9.2.4. Carbonic Anhydrase Inhibitors
9.2.5. Combination Medications
9.3. Market Value Forecast, by End-user, 2020–2026
9.3.2. Ophthalmic Clinics
9.3.3. Ambulatory Surgical Centers
9.4. Market Value Forecast, by Country, 2020–2026
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By End-user
9.5.3. By Country
10. Europe Glaucoma Therapeutics Market Analysis and Forecast
10.2. Market Value Forecast, by Drug Class, 2020–2026
10.2.2. Beta Blockers
10.2.3. Alpha Agonists
10.2.4. Carbonic Anhydrase Inhibitors
10.2.5. Combination Medications
10.3. Market Value Forecast, by End-user, 2020–2026
10.3.2. Ophthalmic Clinics
10.3.3. Ambulatory Surgical Centers
10.4. Market Value Forecast, by Country/Sub-region, 2020–2026
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Glaucoma Therapeutics Market Analysis and Forecast
11.2. Market Value Forecast, by Drug Class, 2020–2026
11.2.2. Beta Blockers
11.2.3. Alpha Agonists
11.2.4. Carbonic Anhydrase Inhibitors
11.2.5. Combination Medications
11.3. Market Value Forecast, by End-user, 2020–2026
11.3.2. Ophthalmic Clinics
11.3.3. Ambulatory Surgical Centers
11.4. Market Value Forecast, by Country/Sub-region, 2020–2026
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Glaucoma Therapeutics Market Analysis and Forecast
12.2. Market Value Forecast, by Drug Class, 2020–2026
12.2.2. Beta Blockers
12.2.3. Alpha Agonists
12.2.4. Carbonic Anhydrase Inhibitors
12.2.5. Combination Medications
12.3. Market Value Forecast, by End-user, 2020–2026
12.3.2. Ophthalmic Clinics
12.3.3. Ambulatory Surgical Centers
12.4. Market Value Forecast, by Country/Sub-region, 2020–2026
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Glaucoma Therapeutics Market Analysis and Forecast
13.2. Market Value Forecast, by Drug Class, 2020–2026
13.2.2. Beta Blockers
13.2.3. Alpha Agonists
13.2.4. Carbonic Anhydrase Inhibitors
13.2.5. Combination Medications
13.3. Market Value Forecast, by End-user, 2020–2026
13.3.2. Ophthalmic Clinics
13.3.3. Ambulatory Surgical Centers
13.4. Market Value Forecast, by Country/Sub-region, 2020–2026
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix
14.2. Market Share Analysis, by Company (2018)
14.3. Company Profiles
14.3.1. Allergan plc
126.96.36.199. Company Overview (HQ, Business Segments, Employee Strength)
188.8.131.52. Financial Overview
184.108.40.206. Product Portfolio
220.127.116.11. SWOT Analysis
18.104.22.168. Strategic Overview
14.3.2. Merck & Co., Inc.
22.214.171.124. Company Overview (HQ, Business Segments, Employee Strength)
126.96.36.199. Financial Overview
188.8.131.52. Product Portfolio
184.108.40.206. SWOT Analysis
220.127.116.11. Strategic Overview
14.3.3. Novartis AG
18.104.22.168. Company Overview (HQ, Business Segments, Employee Strength)
22.214.171.124. Financial Overview
126.96.36.199. Product Portfolio
188.8.131.52. SWOT Analysis
184.108.40.206. Strategic Overview
14.3.4. Pfizer Inc.
220.127.116.11. Company Overview (HQ, Business Segments, Employee Strength)
18.104.22.168. Financial Overview
22.214.171.124. Product Portfolio
126.96.36.199. SWOT Analysis
188.8.131.52. Strategic Overview
14.3.5. Santen Pharmaceuticals Co. Ltd.
184.108.40.206. Company Overview (HQ, Business Segments, Employee Strength)
220.127.116.11. Financial Overview
18.104.22.168. Product Portfolio
22.214.171.124. SWOT Analysis
126.96.36.199. Strategic Overview
14.3.6. Valeant Pharmaceuticals International, Inc.
188.8.131.52. Company Overview (HQ, Business Segments, Employee Strength)
184.108.40.206. Financial Overview
220.127.116.11. Product Portfolio
18.104.22.168. SWOT Analysis
22.214.171.124. Strategic Overview
14.3.7. Aerie Pharmaceuticals Inc.
126.96.36.199. Company Overview (HQ, Business Segments, Employee Strength)
188.8.131.52. Product Portfolio
184.108.40.206. SWOT Analysis
220.127.116.11. Strategic Overview
Fact.MR offers custom research services that help clients to get specific research solutions
We are committed towards customer satisfaction and quality service.